171 filings
Page 4 of 9
6-K
z3vgtn2h
28 Jul 21
MediWound Announces Positive Outcome of Interim Assessment for its
7:05am
6-K
uugdb6t
26 Jul 21
MediWound Announces Initiation of U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
7:05am
6-K
ykbp2syxd499ruzcltt
20 Jul 21
MediWound Announces Positive Topline Results from Phase 3 Pediatric
7:05am
6-K
k9p kc7hl90ccru5
29 Jun 21
MediWound Receives Complete Response Letter from U.S. FDA for NexoBrid
8:54am
6-K
lorwh
15 Jun 21
Current report (foreign)
4:06pm
6-K
hjeskjljdlw 3gsz
5 May 21
Current report (foreign)
4:15pm
6-K
9fcfra4bw oq0l512
5 May 21
MediWound Reports First Quarter 2021 Financial Results
7:05am
6-K
kci4k8 4d
22 Apr 21
Current report (foreign)
7:39am
6-K
5k512vqs ri
25 Feb 21
MediWound Reports Fourth Quarter and Full-Year 2020 Financial Results
7:05am
6-K
x41o9
22 Feb 21
MediWound Launches Clinical Development Program for Treatment of
6:30am
6-K
0aax5z
11 Jan 21
MediWound Provides Progress Update on Its EscharEx Clinical
7:05am
6-K
fjz62uaayxhlha
10 Nov 20
MediWound Reports Third Quarter 2020 Financial Results
7:06am
6-K
xjfv5ycnc3
28 Oct 20
MediWound Completes Enrollment Stage of its NexoBrid Phase 3 Pediatric Study
7:00am
6-K
5asmx0keq26
16 Sep 20
MediWound Announces FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
7:35am
6-K
n7peac5ogm
25 Aug 20
MediWound and Vericel Announce Acceptance of the First Delivery of NexoBrid
7:05am
6-K
clnt8
6 Aug 20
MediWound Reports Second Quarter 2020 Financial Results and Provides Corporate Update
7:05am
6-K
yzc9g6e7rb ul48
2 Jul 20
Current report (foreign)
4:05pm
6-K
d6wcyre9
30 Jun 20
MediWound Announces Submission of Biologics License Application to
7:05am
6-K
7kusbqk fldvl
20 May 20
Current report (foreign)
4:15pm
6-K
46n5rhu6ewm08l cutp
20 May 20
MediWound Reports First Quarter 2020 Financial Results and Provides Corporate Update
7:05am